May 29, 2020
New Number of Shares and Votes in Moberg Pharma AB (publ)
Mar 23, 2020
Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015
Feb 04, 2020
Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference
Jan 22, 2020
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
Dec 12, 2019
Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
Oct 21, 2019
Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea
Oct 18, 2019
Changes to Moberg Pharma's Management Team
May 14, 2019
Moberg Pharma AB Interim Report January - March 2019
Apr 16, 2019
Moberg Pharma Annual Report 2018
Apr 08, 2019
Proposed Management Changes at Moberg Pharma
Apr 01, 2019
Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989
Mar 29, 2019
Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million
Mar 22, 2019
Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe
Feb 11, 2019
Moberg Pharma AB Year-end Report 2018
Feb 11, 2019
Moberg Pharma Divests Its OTC-business for USD 155 Million and Secures New Funding for MOB-015 in Transformational Transaction
Sep 18, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
May 15, 2018
Bulletin from Moberg Pharma's AGM 2018
Apr 10, 2018
Moberg Pharma Annual Report 2017
Feb 13, 2018
Moberg Pharma AB Year-end Report 2017
Jan 15, 2018
Moberg Pharma Receives Favorable Outcome From NAD - Main Competitor to Discontinue Current Marketing